Acquisitions:
1. Sun Pharma signs Definitive Agreement to Acquire Organon in US$11.75 Billion Deal.
2. Lupin completes acquisition of VISUfarma.
3. Emami Ltd to acquire 100% stake in Axiom Ayurveda in deal worth up to INR ?200 crore ( US$21.05 Million).
4. Zyax Chem secures 26% stake in Gaymed Labs to focus on eye care.
5. Rubicon Research enters CNS formulations market with acquisition of Arinna Lifesciences.
6. Eli Lilly to buy Ajax Therapeutics for up to US$2.3 Billion in blood cancer bet.
7. IKS Health to acquire TruBridge in US$557 Million deal.
8. Getinge has acquired Pennamed, a UK-based distributor of endoscopic consumables serving National Health Service (NHS) and independent healthcare providers.
9. Axsome Therapeutics acquires Takeda’s selective PDE10A inhibitor balipodect.
Licensing:
1. OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck.
2. Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to support ADC development and manufacturing.
3. Aurigene Pharma collaborates with Alveus Therapeutics to advance peptide and small molecule programs for metabolic diseases.
4. Merck & Google Cloud ink US$1 Billion AI deal to build “Agentic” pharma future.
5. Galen inks new licensing partnership with Istituto Gentili.
Investments/Fund Raising:
1. Gene therapy biotech Ray Therapeutics has announced the closing of a US$125 Million series B financing to support the company’s vision restoration candidates for patients with retinal degeneration.
2. Vivatides raises US$54 Million to push RNA drugs beyond liver targets.
Co-Development:
1. PAGE and 8chili partner to launch India’s first AI and VR powered pharma training platform.
Aagami Updates:
2. New Partner Appointment: Dr. John Zhu, a native Chinese speaker and Ph.D. in Pharmaceutical Sciences, joins Aagami as Partner Consultant with 25+ years of experience in cross-border M&A, licensing, and global strategy. As Co-founder of Mayewell Capital, he bridges the U.S. and Chinese markets to provide expert leadership and clinical development guidance.
3. ChinaBio® 2026: Aagami’s CEO has successfully concluded a strategic mission to China, highlighted by the ChinaBio® 2026. With 40+ high-level strategic one-on-one meetings with decision makers, Aagami is now well set to serve wider markets like China, while strengthening existing relationships.
4. Our calendar is now open for meetings at BIO Internation Convention (Jun 22-25|San Diego). Please send your requests before the schedule gets full.
Select opportunities available:
For Partnering/Licensing/ Co-development:
2. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.
3. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients 40 to 72 years of age).
5. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
6. Smart Polymeric best-in-class delivery system platform with long-acting injectables pipeline. Seeking partnering and investment.
7. Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.
8. Seeking Licensing / Co-development / Platform Partnering: FDA-validated Ionic Liquid (IL) enabled drug delivery platform addressing solubility, permeability, and bioavailability challenges. Enables non-invasive systemic delivery via transdermal and oral routes, including peptides and nucleic acids. Clinically validated with an FDA-approved IL-enabled product and demonstrated ~6× improvement in oral bioavailability (e.g., Semaglutide). Platform licensing, molecule-specific licensing, and joint R&D collaborations available. Email us about your challenging molecules at action@aagami.com
9. Available for Licensing/Co-development: Biosimilars such as Adalimumab, Rituximab, & Infliximab with ~2028 market launch timeline.
For Acquisition:
1. [URGENT] Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. Few discussions already ongoing.
2. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology for Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc.
3. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.
For Investment:
1. Partnering/Investment open for optimized technology from AU to farm Beta carotene and other valuable nutraceuticals from Algae.
a. The enhanced version of a globally proven Tech brings significant cost efficiency and productivity.
b. An Investment/partnering deal will finalize first commercial-scale facility, optimize corporate governance, and prepare for global expansion, offering strategic partners a low-risk entry into a high-demand, clean-label supply chain.
2. High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market for 4 years). Exit via an IPO, strategic M&A, or private equity buyout.
Hope you found the content useful. We welcome your feedback and queries.